Senseonics Holdings Inc Dossier
Qualitative Analysis
Business overview
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems designed to improve the lives of people with diabetes. The company's flagship product line, Eversense, includes the Eversense E3 and the newly launched Eversense 365. Unlike traditional non-implantable CGM systems that require replacement every 7 to 14 days, Eversense utilizes an under-the-skin fluorescence-based sensor that continually and accurately measures glucose levels for up to 180 and 365 days, respectively. The system is completed by a removable, rechargeable smart transmitter and a mobile application for real-time monitoring.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning all commercial, sales, marketing, and distribution operations for the Eversense CGM system back in-house from former exclusive partner Ascensia Diabetes Care.
Expected impact: Eliminates revenue-sharing drag, increases top-line revenue recognition to 100%, and expands gross margins to a targeted 55% to 58% in 2026.
Investing heavily in direct-to-consumer marketing channels to drive patient awareness and brand adoption for the Eversense 365-day CGM.
Expected impact: Aims to sustain and accelerate new patient growth, building on the 103% U.S. new patient growth achieved in 2025.
Partnering with Welldoc to develop a customized, next-generation mobile application for the Eversense 365 CGM system, integrating Apple Health and Google Health Connect.
Expected impact: Enhances user experience, improves patient retention, and strengthens the competitive positioning of the Eversense ecosystem.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of U.S. marketing, sales, and distribution assets to bring Eversense commercialization entirely in-house, streamlining operations and capturing full product economics.
Financial impact: Enables 100% revenue recognition in the U.S. and drives gross margin expansion to over 50%.
Acquisition of commercial assets and rights related to Eversense CGM activities in Italy, Germany, Spain, and Sweden to establish direct commercial control in Europe.
Financial impact: Cash consideration at closing is based on the net book value of related assets and assumed liabilities. Supported by a Transition Services Agreement for logistics, IT, and finance.
Strategic Partnerships
Integrates the Eversense 365 CGM system with Sequel's twiist Automated Insulin Delivery (AID) system, offering the first one-year CGM integrated with an AID pump.
Terms: Not disclosed
Collaborating to develop a customized, next-generation mobile application for the Eversense 365 CGM to enhance digital health connectivity and user experience.
Terms: Not disclosed